High-Value Turnover and Trading Volumes
On the trading day, Sun Pharma witnessed a total traded volume of 9,46,470 shares, translating into an impressive traded value of ₹181.98 crores. This substantial turnover places the stock among the top equity performers by value, underscoring heightened market activity and investor confidence. The stock opened at ₹1,889.9 and surged to an intraday high of ₹1,942.1, marking a 2.7% gain from the previous close of ₹1,888.2. The last traded price (LTP) stood at ₹1,934.6 as of 09:44:47 IST, signalling sustained buying momentum.
Technical Strength and Trend Reversal
Sun Pharma’s price action reveals a notable trend reversal after two consecutive days of decline. The stock outperformed its sector by 1.08% and the broader Sensex by 1.77 percentage points, with a 1-day return of 2.43% compared to the sector’s 1.78% and Sensex’s 0.66%. Importantly, the share price is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating a strong bullish technical setup. The stock also hit a new 52-week high of ₹1,933.6 during the session, reinforcing the positive momentum.
Institutional Interest and Delivery Volumes
Investor participation has been on the rise, as evidenced by the delivery volume of 15.71 lakh shares on 8 July 2026, which surged by 67.14% compared to the 5-day average delivery volume. This increase in delivery volume suggests that investors are not merely trading intraday but are holding shares, signalling confidence in the company’s medium to long-term prospects. The stock’s liquidity is also noteworthy, with the capacity to handle trade sizes of up to ₹7.73 crores based on 2% of the 5-day average traded value, making it an attractive option for institutional investors and large order flows.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
Mojo Score Upgrade and Market Capitalisation
Sun Pharmaceutical Industries Ltd’s Mojo Score currently stands at 74.0, reflecting a strong Buy rating. This represents an upgrade from the previous Hold grade, effective from 8 June 2026. The improved Mojo Grade is indicative of enhanced fundamentals, technical strength, and positive market sentiment. As a large-cap entity with a market capitalisation of ₹4,64,031.38 crores, Sun Pharma remains a cornerstone stock within the Pharmaceuticals & Biotechnology sector, commanding significant investor attention and institutional interest.
Sectoral and Market Context
The Pharmaceuticals & Biotechnology sector has shown resilience amid broader market fluctuations, with Sun Pharma’s outperformance highlighting its leadership position. The stock’s ability to outperform both its sector and the Sensex on a day of strong value turnover suggests robust underlying demand and favourable investor perception. This is further supported by the stock’s consistent trading above key moving averages, signalling sustained upward momentum.
Liquidity and Large Order Flow Dynamics
Liquidity remains a critical factor for institutional investors and large traders, and Sun Pharma’s trading metrics confirm its suitability for sizeable transactions. The stock’s capacity to absorb trade sizes of nearly ₹7.73 crores without significant price disruption is a testament to its market depth. This liquidity, combined with rising delivery volumes, points to strong institutional accumulation and a healthy order book, which bodes well for continued price appreciation.
Curious about Sun Pharmaceutical Industries Ltd from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Outlook and Investor Considerations
Given the recent upgrade in Mojo Grade and the strong technical indicators, Sun Pharma is well-positioned for further gains. The stock’s ability to sustain above critical moving averages and its new 52-week high suggest that the bullish trend may continue in the near term. However, investors should remain mindful of sector-specific risks such as regulatory changes and global pharmaceutical market dynamics.
Institutional investors are likely to continue their accumulation given the stock’s liquidity and improving fundamentals. The rising delivery volumes reinforce the conviction that the current price action is supported by genuine buying interest rather than speculative trading. For long-term investors, the upgraded Buy rating and large-cap status provide additional confidence in the stock’s growth trajectory.
Summary
Sun Pharmaceutical Industries Ltd’s trading session on 9 July 2026 was marked by high-value turnover, strong institutional participation, and a positive technical reversal. The stock’s upgraded Mojo Grade to Buy, combined with its large-cap stature and sector leadership, makes it a compelling choice for investors seeking exposure to the Pharmaceuticals & Biotechnology space. With robust liquidity and sustained investor interest, Sun Pharma is poised to maintain its upward momentum in the coming weeks.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
